Experimental: Rivaroxaban

Phase 3Small molecule

Experimental: Rivaroxaban is one of 22 small molecule programs targeting Antiphospholipid Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Antiphospholipid SyndromeActive, not recruiting

Antiphospholipid SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

29 competitors in Antiphospholipid Syndrome

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

1 2

Coumadin

AAbbott

Approved

3 3

Plaquenil

Alnylam Pharmaceuticals

Phase 3

3 4

Antiplatelet Drug

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Approved

1 5

Benlysta

GGlaxo Dba Glaxosmithkline

Phase 3

1 6

Rituxan

Roche

Phase 2

1 7

Lovenox

Sanofi

Phase 2

1 8

Lescol

Novartis

Phase 2

1 9

Darzalex

Johnson & Johnson

Phase 2

1 10

Brukinsa

BBeOne Medicines

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Antiphospholipid Syndrome1 trial

Rivaroxaban in Thrombotic Antiphospholipid Syndrome

Terminated·UUniversity of Padova·Phase 3·NCT02157272·121 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Experimental: Rivaroxaban. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Experimental: Rivaroxaban compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Experimental: Rivaroxaban. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Padova company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Padova

Experimental: Rivaroxaban

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Antiphospholipid Syndrome1 trial

References

Drug Info

Quick Facts

Related News